Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
Conclusions Once-daily 50-mg ipragliflozin enabled a 30% dose reduction of insulin by Week 24 compared with baseline. No major safety concerns were raised.Clinical Trial RegistrationClinicalTrials.gov (NCT02847091)
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Cholesterol | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Insulin | Japan Health | Study